Ladenburg Thalmann Boosts Price Target on BioDelivery Sciences (BDSI) to $9
More News related to BDSI
- Meda Launches Onsolis(TM) (Fentanyl Buccal Soluble Film) for the Treatment of Breakthrough Cancer Pain in Opioid Tolerant Patients
- BioDelivery Sciences International, Inc. (BDSI) President and Chief Executive Officer to Ring The NASDAQ Stock Market Opening Bell
- BioDelivery Sciences and Meda Launch ONSOLIS (fentanyl buccal soluble film)
- BioDelivery Sciences (BDS) Announces $1.3M U.S. Army Grant
- BioDelivery Sciences Receives $1.3 Million US Army Grant For Investigation of Bioral Amphotericin B in Topical Leishmaniasis
More News related to Analyst Comments
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
- Hemispherx Biopharma (HEB) Reports a Q3 Loss; Comments on FDA Responses
- Wright Medical Group (WMGI) Announces FDA Approval For CONSERVE Plus Total Hip Resurfacing System
- Vascular Solutions (VASC) Receives 501(k) Clearance from U.S. FDA for GuideLiner Catheter
Ladenburg Thalmann raises its price target on BioDelivery Sciences International Inc. (Nasdaq: BDSI) from $6.5 to $9, reiterating their Buy rating.
BioDelivery Sciences International, Inc. operates as a specialty pharmaceutical company in the United States.
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
Analyst CommentsStocks Mentioned
+0.06Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
